Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Tissue factor pathway inhibitor-2 reduces interstitial collagenase degradation of triple-helical collagen and may be of use in the treatment of atherosclerosis. Login. Subscribe. News; Magazines. An ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

Hympavzi targets the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulation protein. In developing the treatment, Pfizer trailed Novo Nordisk’s investigational TFPI ...

But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue factor pathway inhibitor, for patients aged 12 and older with hemophilia A or B who have ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Concizumab is a tissue factor pathway inhibitor (TFPI) antagonist designed to enhance thrombin production by blocking TFPI—a protein that disrupts blood clotting.

Concizumab for hemophilia: Novo Nordisk’s anti-tissue factor pathway inhibitor therapy is under review for prophylactic use in hemophilia A or B with inhibitors. Clinical trial data showed ...